Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors.
Trk receptor Inhibitors Related Products:
SP600125; Danusertib; GW441756; Altiratinib; GNF-5837; Ropotrectinib; Larotrectinib sulfate; ANA-12